MetaCap

Cardiol Therapeutics (CRDL) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed Zura Bio (ZURA) over the past year, losing 11.3% versus a loss of 74.4%. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $89.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%ZURA-74.37%
+145%+30%-85%
Nov 21, 20251 yearNov 20, 2026
CRDL+72.18%ZURA-96.84%
+449%+163%-123%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus ZURA key metrics
MetricCRDLZURA
Share price$0.8626$0.9305
Market cap$110.14M$89.63M
1-day change-2.28%-2.30%
YTD return-9.58%-82.24%
1-year return-11.35%-74.37%
5-year return-60.06%—
EPS (TTM)$-0.24$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-68.65M
52-week high$2.34$7.44
52-week low$0.8417$0.919
Distance from 52-week high-63.14%-87.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+874.96%+759.75%
Average volume1.20M4.47M
Shares outstanding127.69M96.33M
Employees1840
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed ZURA by 63.0 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

CRDL vs ZURA FAQ

Which is bigger, Cardiol Therapeutics or Zura Bio?

Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $89.63M for Zura Bio (ZURA).

Which stock has performed better over the past year, CRDL or ZURA?

CRDL returned -11.35% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons